Celastrol slows the progression of early diabetic nephropathy in rats via the PI3K/AKT pathway
Related Experiment Video
Updated: Dec 4, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Yusong Nie1,2,3, Chengxiao Fu4, Huimin Zhang1
1Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Background:
Diabetic nephropathy serves as one of the most regular microvascular complications of diabetes mellitus and is the main factor that causes end-stage renal disease and incident mortality. As the beneficial effect and minute adverse influence of Celastrol on the renal system requires further elucidation, the renoprotective function of Celastrol in early diabetic nephropathy was investigated.
Methods:
In high-fat and high-glucose diet/streptozotocin-induced diabetic rats which is the early diabetic nephropathy model, ALT, AST, 24 h urinary protein, blood urea nitrogen, and serum creatinine content were observed. Periodic acid-Schiff staining, enzyme-linked immunosorbent assay, immunohistochemical analysis, reverse transcription-polymerase chain reaction, and western blot analysis were used to explore the renoprotective effect of Celastrol to diabetic nephropathy rats and the underlying mechanism.
Results:
High dose of Celastrol (1.5 mg/kg/d) not only improved the kidney function of diabetic nephropathy (DN) rats, and decreased the blood glucose and 24 h urinary albumin, but also increased the expression of LC3II and nephrin, and downregulated the expression of PI3K, p-AKT, and the mRNA level of NF-κB and mTOR.
Conclusion:
Celastrol functions as a potential therapeutic substance, acting via the PI3K/AKT pathway to attenuate renal injury, inhibit glomerular basement membrane thickening, and achieve podocyte homeostasis in diabetic nephropathy.
Insights
Celastrol shows promise in treating early diabetic nephropathy by improving kidney function and reducing blood glucose. It acts through the PI3K/AKT pathway to protect against kidney damage.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Diabetic nephropathy is a major complication of diabetes, leading to end-stage renal disease.
- Celastrol's renoprotective effects and safety profile require further investigation.
Purpose of the Study:
- To investigate the renoprotective function of Celastrol in an early diabetic nephropathy model.
- To elucidate the underlying mechanisms of Celastrol's action.
Main Methods:
- Diabetic rat model induced by high-fat/high-glucose diet and streptozotocin.
- Biochemical assays (ALT, AST, BUN, creatinine, urinary protein).
- Histological, molecular, and cellular analyses (PAS staining, ELISA, IHC, RT-PCR, Western blot).
Main Results:
- High-dose Celastrol improved kidney function, reduced blood glucose and urinary albumin.
- Increased expression of LC3II and nephrin.
- Downregulated PI3K, p-AKT, and mRNA levels of NF-κB and mTOR.
Conclusions:
- Celastrol demonstrates potential as a therapeutic agent for diabetic nephropathy.
- It acts via the PI3K/AKT pathway to reduce renal injury.
- Celastrol helps inhibit glomerular basement membrane thickening and maintain podocyte homeostasis.
More Related Videos
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Related Concept Videos
Cell Specific Gene Expression
Dipeptidyl Peptidase 4 Inhibitors